Pearl Therapeutics, Inc.: Series C $15M

Posted in I - Series C, Q - 1Q10, R - WEST, X - Asthma, X - COPD, XX - CA

Pearl Therapeutics (Redwood City, CA) a clinical-stage pharma company focused on metered dose inhaler products for the treatment of COPD and asthma, closed a $15M Series C financing. Participants include Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.

Feb

2010

Elevation Pharmaceuticals, Inc.: Series A $30M

Posted in I - Series A, Q - 1Q10, R - WEST, X - COPD, X - Respiratory, XX - CA

Elevation Pharmaceuticals (San Diego, CA) a preclinical-stage biopharmaceutical company focused on developing improved inhaled drug therapies for COPD , closed a $30M Series A financing. Participants include Canaan Partners, TPG Growth, Care Capital and Mesa Verde Venture Partners.

Jan

2010

Pulmatrix, Inc.: Series B $30.2M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Antiinfective, X - Asthma, X - COPD, X - Influenza, X - RSV, X - Respiratory, XX - MA

Pulmatrix (Lexington, MA) a clinical-stage biotechnology company focused on the discovery and development of therapies for the treatment and prevention of infectious (COPD, asthma, and cystic fibrosis) and progressive respiratory (influenza, ventilator acquired pneumonia and respiratory syncytial virus (RSV)) diseases, closed a $30.2M Series B financing. Participants include Arch Venture Partners, Novartis Ventures Funds,Polaris Venture [...]

Oct

2009

Inspired Technologies, Inc.: Series B $5.4M

Posted in I - Series B, Q - 3Q09, R - NORTH EAST, X - COPD, X - Device (Oxygen), XX - PA

Inspired Technologies (North Huntingdon, PA) a commercial-stage medical device company focused on auto-titration of oxygen delivery for COPD patients, closed a $5.4M Series B financing. Participants have included Birchmere Ventures, Cardinal Partners, Draper Triangle Ventures and Innovation Ventures.

Apr

2009

Aerovance, Inc.: Series C $38M

Posted in I - Series C, Q - 2Q09, R - WEST, X - Asthma, X - CF, X - COPD, X - Eczema, XX - CA

Aerovance (Berkeley, CA) a clinical-stage company focused on respiratory and allergic diseases, closed a $38M Series C financing. Participants include ProQuest Investments, BB Biotech Ventures, Apax Partners, Clarus Ventures, Alta Partners, Lehman Brothers, NGN Capital and Burrill & Co.

Feb

2009

Mpex Pharmaceuticals, Inc.: Series D $27.5M

Posted in I - Series D, Q - 1Q09, R - WEST, X - Antibacterial, X - CF, X - COPD, XX - CA

Mpex Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on antibiotic therapy in patients with cystic fibrosis and COPD, closed a $27.5M Series D financing. Participants include Investor Growth Capital, SV Life Sciences, HBM BioVentures, Aberdare Ventures and Adams Street Partners.

Dec

2008

Pearl Therapeutics, Inc.: Series A $18M

Posted in I - Series A, Q - 3Q08, R - WEST, X - COPD, X - Respiratory

Pearl Therapeutics (Redwood City, CA) development-stage biopharmaceutical company focused on respiratory disorders, closed a $18M Series A financing. Participants include Clarus Ventures, New Leaf Partners, 5AM Ventures and Nektar Therapeutics.

Nov

2008

Rox Medical, Inc.: Series C $35M

Posted in I - Series C, Q - 2Q08, R - WEST, X - COPD, X - Device (Cardiology)

Rox Medical (San Clemente, CA) medical device company focused on chronic obstructive pulmonary disease, closed a $35M Series C financing. Participants include Essex Woodlands Health Ventures, Domain Associates, Prism VentureWorks and Versant Ventures.

Nov

2008

Breathe Technologies, Inc.: Series B $15M

Posted in I - Series B, Q - 1Q08, R - WEST, X - COPD

Breathe Technologies (Fremont, CA) developer of medical devices for the treatment of chronic obstructive pulmonary disease, closed a $15M Series B financing. Participants include Kleiner Perkins Caufield & Byers, Synergy Partners International, Delphi Ventures and Life Science Angels.

to top of page...